Examples of using Normal hepatic function in English and their translations into Italian
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
-
Official/political
compared to a control group of subjects with normal hepatic function.
patients with mild and moderate hepatic impairment were approximately 38% and 67% lower than that of patients with normal hepatic function, respectively.
in 8 healthy subjects with normal hepatic function.
The study included a control group consisting of 7 HIV-infected patients with normal hepatic function matched with the hepatically impaired patients for age, gender, weight and tobacco use.
mg/m2 twice daily in patients with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function.
in 8 healthy control subjects with normal hepatic function.
The AUC to abiraterone increased by approximately 600% and the fraction of free drug increased by 80% in subjects with severe hepatic impairment compared to subjects with normal hepatic function.
and subjects with normal hepatic function n=18.
clinical laboratory profiles as previous studies of HIV-1 infected subjects with normal hepatic function.
Relative to subjects with normal hepatic function, the geometric mean ratios for Cmax and AUC∞ of canagliflozin were 107% and 110%, respectively, in subjects with Child-Pugh class A(mild hepatic impairment) and 96% and 111%, respectively, in subjects with Child-Pugh class B(moderate) hepatic impairment following administration
0.62 mg/m2 to patients with moderate hepatic impairment resulted in a somewhat higher exposure than after a dose of 1.23 mg/m2 to patients with normal hepatic function.
respectively compared to 22.1 hours in subjects with normal hepatic function.
Compared to healthy subjects with normal hepatic function, the mean steady-state AUC of simeprevir was 2.4-fold higher in non-HCV infected subjects with moderate hepatic impairment(Child-Pugh class B) and 5.2-fold higher in
In a multiple-dose study, a dose reduction of the daily dose to 35 mg in adult patients with moderate hepatic impairment has been shown to provide an AUC similar to that obtained in adult subjects with normal hepatic function receiving the standard regimen see section 4.2.
AUC of febuxostat and its metabolites did not change significantly compared to subjects with normal hepatic function.
respectively, compared to patients with normal hepatic function.
AUClast were 11% and 25% higher respectively for subjects with mild hepatic impairment, and 32% and 46% higher respectively for subjects with moderate hepatic impairment compared to subjects with normal hepatic function.
mg in patients with mild(Child-Pugh class A) or moderate(Child-Pugh class B) hepatic impairment, lesinurad Cmax was comparable and lesinurad AUC was 7% and 33% higher, respectively, compared to individuals with normal hepatic function.
not clinically significantly different than in healthy volunteers with normal hepatic function.